At the 10th International Conference on Frontotemporal Dementias, held August 31 to September 2 in Munich, speakers presented results from three clinical trials. Though conference attendees were disappointed in the initial results, their overall outlook was hopeful. “Now that we know the major pathways involved in frontotemporal lobar degeneration, we know what to target and what to look for in trials,” said conference co-organizer Manuela Neumann of the German Center for Neurodegenerative Diseases (DZNE). There was widespread agreement that FTD trials are becoming more rigorous and biomarker-based, improving the odds of seeing a treatment effect. Read the full ALZFORUM article here.